These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 3387519)

  • 21. Haloperidol and reduced haloperidol plasma levels in selected schizophrenic patients.
    Ereshefsky L; Davis CM; Harrington CA; Jann MW; Browning JL; Saklad SR; Burch NR
    J Clin Psychopharmacol; 1984 Jun; 4(3):138-42. PubMed ID: 6736273
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Depot haloperidol treatment in outpatients with schizophrenia on monotherapy: impact of CYP2D6 polymorphism on pharmacokinetics and treatment outcome.
    Panagiotidis G; Arthur HW; Lindh JD; Dahl ML; Sjöqvist F
    Ther Drug Monit; 2007 Aug; 29(4):417-22. PubMed ID: 17667795
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical response and plasma haloperidol levels in schizophrenia.
    Mavroidis ML; Kanter DR; Hirschowitz J; Garver DL
    Psychopharmacology (Berl); 1983; 81(4):354-6. PubMed ID: 6419263
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Plasma neuroleptic concentration: in search of a therapeutic window.
    Potkin S; Hahn R; Sramek J
    Clin Neuropharmacol; 1986; 9 Suppl 4():256-8. PubMed ID: 2882840
    [No Abstract]   [Full Text] [Related]  

  • 25. Significant dose effect of carbamazepine on reduction of steady-state plasma concentration of haloperidol in schizophrenic patients.
    Yasui-Furukori N; Kondo T; Mihara K; Suzuki A; Inoue Y; Kaneko S
    J Clin Psychopharmacol; 2003 Oct; 23(5):435-40. PubMed ID: 14520118
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Blood levels of haloperidol and thioridazine during maintenance neuroleptic treatment of schizophrenic outpatients.
    Shvartsburd A; Sajadi C; Morton V; Mirabi M; Gordon J; Smith RC
    J Clin Psychopharmacol; 1984 Aug; 4(4):194-8. PubMed ID: 6470190
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Negative correlation between alpha-1-acid-glycoprotein plasma level and response to haloperidol in the acute treatment of schizophrenia.
    Levinson I; Levine S
    Biol Psychiatry; 1995 Aug; 38(3):198-200. PubMed ID: 7578667
    [No Abstract]   [Full Text] [Related]  

  • 28. Haloperidol decanoate in schizophreniform disorders. Clinical and neuroendocrine aspects.
    Meco G; Casacchia M; Attenni M; Iafrate A; Castellana F; Ecari U
    Acta Psychiatr Belg; 1983; 83(1):57-68. PubMed ID: 6613612
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Plasma clozapine levels and clinical benefit.
    Greenberg WM
    J Clin Psychiatry; 1995 Nov; 56(11):535-6. PubMed ID: 7592511
    [No Abstract]   [Full Text] [Related]  

  • 30. Neuroleptic radioreceptor activity and clinical outcome in schizophrenia.
    Contreras S; Alexander H; Faber R; Bowden C
    J Clin Psychopharmacol; 1987 Apr; 7(2):95-8. PubMed ID: 3584527
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A "therapeutic window" for haloperidol?
    Miller DD; Hershey LA
    J Clin Psychopharmacol; 1986 Aug; 6(4):250-1. PubMed ID: 3734149
    [No Abstract]   [Full Text] [Related]  

  • 32. Haloperidol levels and clinical response.
    Cohen BM; Baldessarini RJ
    Am J Psychiatry; 1981 Nov; 138(11):1513-4. PubMed ID: 7294231
    [No Abstract]   [Full Text] [Related]  

  • 33. Combination therapy with haloperidol and orphenadrine in schizophrenia. A clinical and pharmacokinetic study.
    Altamura AC; Buccio M; Colombo G; Terzi A; Cazzullo CL
    Encephale; 1986; 12(1):31-6. PubMed ID: 3698889
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Behavioral prediction of response to haloperidol: a test dose strategy.
    Neborsky R; Janowsky D; Munson E; Hornbeck C; Depry D
    J Clin Psychiatry; 1982 Apr; 43(4):157-8. PubMed ID: 7068547
    [No Abstract]   [Full Text] [Related]  

  • 35. Effect of chlorpromazine and clozapine on plasma concentrations of haloperidol in a patient with schizophrenia.
    Allen SA
    J Clin Pharmacol; 2000 Nov; 40(11):1296-7. PubMed ID: 11075316
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fluoxetine augmentation of haloperidol in chronic schizophrenia.
    Shim JC; Kelly DL; Kim YH; Yoon YR; Park JH; Shin JG; Conley RR
    J Clin Psychopharmacol; 2003 Oct; 23(5):520-2. PubMed ID: 14520132
    [No Abstract]   [Full Text] [Related]  

  • 37. Serum haloperidol concentrations and clinical response in acute psychosis.
    Miller DD; Hershey LA; Duffy JP; Abernethy DR; Greenblatt DJ
    J Clin Psychopharmacol; 1984 Dec; 4(6):305-10. PubMed ID: 6511996
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Amoxapine as an antipsychotic: comparative study versus haloperidol.
    Chaudhry IB; Husain N; Khan S; Badshah S; Deakin B; Kapur S
    J Clin Psychopharmacol; 2007 Dec; 27(6):575-81. PubMed ID: 18004123
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neuroleptic levels by radioreceptor assay and clinical response during treatment of acute exacerbation of schizophrenia--some preliminary findings.
    Greenberg JS; Brown WA; Laughren TP; Krantz J
    Psychopharmacol Bull; 1983; 19(1):74-6. PubMed ID: 6131470
    [No Abstract]   [Full Text] [Related]  

  • 40. Clinical response and serum neuroleptic levels in childhood schizophrenia.
    Meyers B; Tune LE; Coyle JT
    Am J Psychiatry; 1980 Apr; 137(4):483-4. PubMed ID: 7361939
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.